Type 2 Diabetes

An analysis of data from the Health Professionals Follow-Up Study suggests incorporating weight training into physical activity regimens was associated with reduced mortality in patients with or without type 2 diabetes, with the association in those without diabetes present even after adjustment for aerobic activity levels.

Using data from the UK Biobank study, a team of investigators from the University of Exeter determined undiagnosed cases of type 2 diabetes could be identified more than 2 years earlier if universal screening programs were implemented for middle-aged adults.

An analysis of data from a pair of studies examining cardiovascular risk in individuals from countries in Europe provides insight into an apparent increase in the likelihood of developing type 2 diabetes among people with a history of exposure to antibiotics.

An analysis of data from the EPIC study provides insight into an apparent increase in risk of having an advanced stage cancer at time of diagnosis for patients with cardiometabolic diseases compared to their counterparts without cardiometabolic diseases.

In this special edition episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, break down what the approval of teplizumab means for type 1 diabetes. During the episode, hosts take a deep dive into type 1 diabetes staging and hypothesize around the role of CDCES in educating primary care and other specialties to optimize the potential of teplizumab.

On November 17, the US FDA announced the approval of teplizumab (Tzield), which is administered through IV infusion once daily for 14 consecutive days, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.

A study published in Diabetologia discovered that individuals who are exposed to high light pollution while they sleep show a greater risk of developing type 2 diabetes.

Insulin glargline-aglr is the second approved interchangeable biosimilar insulin product to insulin glargine indicated to improve glycemic control in patients with diabetes mellitus.

Kim Zuber, MS, PA-C, and Jane Davis, DNP, provide perspective on the recent consensus statement on management of chronic kidney disease from the American Diabetes Association and the Kidney Disease Improving Global Outcomes group.

A Cedars-Sinai-led analysis of data from the PROCEED study provides insight into risk factors and clinical predictors of diabetes among a cohort of adult patients with chronic pancreatitis.

Dr Elaine M. Apperson shares diabetes prevention strategies and mitigating disease complications in the pediatric population as well as advice for health care practitioners managing the disease.

Elaine M. Apperson, MD, addresses early intervention and technologies for monitoring type 1 diabetes for disease management.

In this episode, our hosts are joined by Lydia Alexander, MD, president-elect of the Obesity Medicine Association, to discuss the updates in the landscape of obesity management as well as a deep dive into the recent American Gastroenterological Association guidelines for pharmacological management and the OMA's annual meeting.

An expert pediatric endocrinologist discusses raising awareness among pediatricians about type 1 diabetes.

Dr Elaine M. Apperson provides insight on when to refer patients with type 1 diabetes to pediatric endocrinology and comments on offering sibling antibody screening.

In this column, Gregory Weiss, MD, reviews recent data suggesting lipid biomarkers could be used to identify patients at increased risk of developing diabetic neuropathy later in life.

Following a session examining the application of the latest iterations of cardiometabolic health guidelines, Diana Isaacs, PharmD, discusses how the evolving role of diabetes, and recognition of this role, in cardiovascular disease is reflected at the American Heart Association 2022 Scientific Sessions.

The treatment reduced UACR by 37.1% and LDLc by 17.12 compared to placebo.

The late-breaking findings presented at AHA 2022 suggest the incidence of CV events was not lower among patients who received pemafibrate compared with those who received placebo.

In this column, Gregory Weiss, MD, provides perspective on a recent study providing evidence in support of metformin as a potential therapeutic option for treatment of atrial fibrillation.

A new user, active comparator analysis suggests use of GLP-1 receptor agonists and SGLT2 inhibitors was associated with a reduced risk of severe COPD exacerbations compared with use of sulfonylureas among people with diabetes and COPD.

An analysis of data from the Netherlands Epidemiology and Obesity study suggests those who engaged in physical activity in the afternoons or evening conferred the greatest benefit in terms of insulin resistance.

Elaine M. Apperson, MD, reviews screening guidelines for the management of type 1 diabetes.

An expert pediatric endocrinologist addresses awareness of family history of type 1 diabetes as well as differentiating within type 1 and type 2 disease.

An analysis of NHANES data from adults with diabetes provides insight into the impact of food insecurity and poor diet quality on diabetes management.